Clinical Trial Update: ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial [Phase 4]

View source ↗

Summary

Phase 4 multi-center prospective trial evaluating ZSDT for relapsed/refractory mantle cell lymphoma after BTK inhibitor failure; the study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• ZSDT

Snippet

Sponsor: Zhengzhou University | Conditions: Mantle Cell Lymphoma (MCL) | Phase 4 | Status: NOT_YET_RECRUITING